TrialSignal
Clinical trial intelligence report
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT01110473-Jul 28, 2026
NCT ID
NCT01110473
Status
COMPLETED
Phase
PHASE1
Sponsor
AbbVie (prior sponsor, Abbott)
Executive brief
Investment-Ready Snapshot
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies is a PHASE1 clinical asset sponsored by AbbVie (prior sponsor, Abbott) in Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, B-cell Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia. SEO and diligence focus: ABT-348, ABT-348, ABT-348 and azacitidine, ABT-348, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01110473
Indication
Acute Lymphoblastic Leukemia
Modality
small molecule
Target
ABT-348, ABT-348, ABT-348 and azacitidine, ABT-348
Intervention
ABT-348, ABT-348, ABT-348 and azacitidine, ABT-348
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.